| Literature DB >> 29168236 |
Masaya Okada1, Taizo Tasaka2, Kazuhiro Ikegame1, Nobuyuki Aotsuka3, Takeshi Kobayashi4, Yuho Najima4, Yoshiko Matsuhashi2, Hideho Wada2, Hirotoshi Tokunaga2, Shinichi Masuda3, Yoshikazu Utsu3, Satoshi Yoshihara1,5, Katsuji Kaida1, Takashi Daimon6, Hiroyasu Ogawa1.
Abstract
Cord blood transplantation (CBT) is associated with delayed hematopoietic recovery and graft failure. To overcome these problems, we conducted a prospective, multicenter phase II study of intrabone marrow transplantation in which patients received reduced-intensity conditioning without anti-thymocyte globulin (ATG). The primary endpoint was the probability of full donor engraftment. Forty patients with hematologic malignancies were enrolled. Cord blood (CB) cells were injected without washing into 4 iliac bone sites (2 at each hemipelvis), at which approximately 6 mL of CB was administered at one site with local anesthesia. Full donor engraftment rate was 86.8%. The cumulative incidence of neutrophil and platelet engraftment was 86.4% and 85.5%, respectively. The median time to neutrophil (>0.5 × 109 /L) and platelet (2.0 × 109 /L) recovery was 17.5 and 44 days, respectively. The probability of severe acute graft-vs-host disease (GVHD) was 47.5%. The cumulative incidence of extensive chronic GVHD was 3.0%. The probability of relapse and non-relapse mortality was 30.4% and 28.0%, respectively. The survival rate at 3 years was 45.6%, although most patients were at an advanced stage. These results suggest that our intrabone marrow-CBT procedure without using ATG improves hematopoietic recovery and decreases the incidence of chronic GVHD, but does not decrease the incidence of acute GVHD.Entities:
Keywords: cord blood transplantation; engraftment; intrabone transplantation
Mesh:
Year: 2018 PMID: 29168236 DOI: 10.1111/ejh.12999
Source DB: PubMed Journal: Eur J Haematol ISSN: 0902-4441 Impact factor: 2.997